

Date: 05/11/20

Location: Virtual

Minutes: Draft

Committee members present:	
Anthony Wierzbicki (AW)	Present for notes 1 – 9
Virginia Aylett (VA)	Present for notes 1 – 9
Tara Bashford (TB)	Present for notes 1 – 9
Ivan Benett (IB)	Present for notes 3 – 9
Roy Connell (RC)	Present for notes 1 – 6
Grainne Connolly (GC)	Present for notes 2 – 9
Jan Dudley (JD)	Present for notes 1 – 9
Deepa Kariyawasam (DK)	Present for notes 1 – 9
Arif Khwaja (AK)	Present for notes 1 – 9
Andrew Lewington (AL)	Present for notes 1 – 9
Fiona Loud (FL)	Present for notes 1 – 9
Catherine Pogson (CP)	Present for notes 1 – 9
Nicola Thomas (NT)	Present for notes 1 – 9

In attendance:		
Victoria Axe (VA)	Commissioning Manager	Present for notes 1 – 9
Steph Armstrong (SA)	Technical Analyst Health Economics	Present for notes 1 – 9
Chris Carmona (CC)	Senior Technical Analyst	Present for notes 1 – 9
Lucy Beggs (LB)	Technical Adviser – Health Economics	Present for notes 1 – 9
Rebecca Boucher (RB)	Pathway Editor	Present for notes 1 – 4
Anne-Louise Clayton (AC)	Editor	Present for notes 1 – 9
Jackie Durkin (JD)	Administrator	Present for notes 1
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 9
Vonda Murray (VM)	Project Manager	Present for notes 1 – 9
Joshua Pink (JP)	Technical Adviser – Health Economics	Present for notes 1 – 9

Kidney Suite GComm 15 minutes

Philip Williams (PW)	Resource Impact Lead	Present for notes 1 – 9
Susan Spiers (SP)	Associate Director	Present for notes 1 – 9

Apologies:

Clare Allinson	Committee member
Susan Spiers	Associate Director
Rajib Pal	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 15th committee meeting on Kidney Injury & Disease. The Chair welcomed to the meeting; committee members, and NICE attendees.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Reviewing new evidence, recommendation and research recommendation review for;
 - adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it.
 - which children and young people should be tested for CKD.
 - people with CKD, what eGFR threshold should trigger investigation of anaemia being due to CKD.
 - what is the best combination of measures of kidney function and markers of kidney damage to identify increased risk of progression in adults, children and young people with CKD?
- Review the recommendations for all review questions where no new evidence/queries have been presented to the committee at GComm14/15

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, did not prevent the attendees from fully participating in the meeting. No new interests declared.

The Chair asked the Committee if it wanted any changes made to the minutes of GComm 12 and GComm13. The Committee agreed that the minutes were a true and accurate account of the meetings.

2. Pathway presentation

The Chair introduced RB Pathway Editor, who presented to the committee about the NICE

Kidney Suite GComm 15 minutes

pathway. The Chair thanked RB for her presentation.

3. RQ1.2 In adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it?

- Reruns
- Recommendation review
- Research recommendations

The Chair introduced YM Technical Analyst, who presented the evidence for what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it in adults, children and young people from black, Asian and other minority ethnic groups with CKD. The Chair thanked YM for her presentation. The Chair facilitated a discussion around the recommendations.

4. RQ1.5 Which children and young people should be tested for CKD?

- Reruns
- Recommendation review
- Research recommendations

The Chair introduced YM Technical Analyst, who presented the evidence for which children and young people should be tested for CKD. The Chair thanked YM for her presentation. The Chair facilitated a discussion around the recommendations.

5. RQ6.1 For people with CKD, what eGFR threshold should trigger investigation of anaemia being due to CKD?

- Reruns
- Recommendation review
- Research recommendations

The Chair introduced YM Technical Analyst, who presented the evidence for people with CKD, what eGFR threshold should trigger investigation of anaemia being due to CKD. The Chair thanked YM for her presentation. The Chair facilitated a discussion around the recommendations.

6. RQ2.1 What is the best combination of measures of kidney function and markers of kidney damage to identify increased risk of progression in adults, children and young people with CKD?

- Reruns
- Recommendation review
- Research recommendations

The Chair introduced JP Technical Adviser – Health Economics who presented a number of questions to the committee on what is the best combination of measures of kidney function and markers of kidney damage to identify increased risk of progression in adults, children and young people with CKD. The Chair thanked JP for his presentations. The Chair facilitated a discussion around the

Kidney Suite GComm 15 minutes

recommendations.

7. RQ1.3 In children and young people with CKD, what is the accuracy of reagent strips for detecting protein and blood in urine?

RQ1.4 What is the accuracy of albumin:creatinine ratio versus protein:creatinine ratio measurements to quantify proteinuria in children and young people with CKD?

RQ5.1 For people with stage 4 or 5 CKD who are not on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes?

RQ5,2 For people with stage 5 CKD who are on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes?

RQ7.1 What should be the aspirational haemoglobin target range for children and young people undergoing treatment for anaemia in CKD?

RQ8.1 For people with stage 5 CKD who are on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes?

- **Recommendation review**
- **Research recommendations review**

The Chair introduced CC Technical Senior Analyst who presented several questions to the committee. The Chair thanked CC for his presentations. The Chair facilitated a discussion around the recommendations.

8. Guideline - next steps

The Chair outlined the process, and key dates in preparing the guideline for publication.

9. AOB, Summary and next steps

The Chair thanked the committee for their time and contribution to the meeting and reminded the committee of the date and time of the next committee meeting

Date of next meeting: 22/3/21 – 08:45 to 17:00

Location of next meeting: Virtual